GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Doseology Sciences Inc (OTCPK:DOSEF) » Definitions » Beneish M-Score

Doseology Sciences (Doseology Sciences) Beneish M-Score : -4.71 (As of Jun. 23, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Doseology Sciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.71 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Doseology Sciences's Beneish M-Score or its related term are showing as below:

DOSEF' s Beneish M-Score Range Over the Past 10 Years
Min: -9.06   Med: -5.42   Max: 14.64
Current: -4.71

During the past 4 years, the highest Beneish M-Score of Doseology Sciences was 14.64. The lowest was -9.06. And the median was -5.42.


Doseology Sciences Beneish M-Score Historical Data

The historical data trend for Doseology Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Doseology Sciences Beneish M-Score Chart

Doseology Sciences Annual Data
Trend Jun20 Jun21 Jun22 Jun23
Beneish M-Score
- - - -9.06

Doseology Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.64 -9.06 -6.89 -5.42 -4.71

Competitive Comparison of Doseology Sciences's Beneish M-Score

For the Biotechnology subindustry, Doseology Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Doseology Sciences's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Doseology Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Doseology Sciences's Beneish M-Score falls into.



Doseology Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Doseology Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5682+0.528 * -4.1475+0.404 * 0+0.892 * 2.2+0.115 * 0.8203
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2935+4.679 * -0.053381-0.327 * 0.0137
=-4.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $0.01 Mil.
Revenue was 0.025 + 0.01 + 0.034 + 0.008 = $0.08 Mil.
Gross Profit was 0.003 + 0.008 + 0.021 + 0.029 = $0.06 Mil.
Total Current Assets was $0.84 Mil.
Total Assets was $0.84 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $0.33 Mil.
Total Current Liabilities was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -0.03 + -0.083 + -0.058 + -0.863 = $-1.03 Mil.
Non Operating Income was 0 + 0.014 + 0 + -0.741 = $-0.73 Mil.
Cash Flow from Operations was -0.021 + -0.098 + -0.044 + -0.099 = $-0.26 Mil.
Total Receivables was $0.01 Mil.
Revenue was 0.007 + 0.013 + 0.004 + 0.011 = $0.04 Mil.
Gross Profit was 0.001 + 0.004 + -0.004 + -0.116 = $-0.12 Mil.
Total Current Assets was $1.67 Mil.
Total Assets was $2.11 Mil.
Property, Plant and Equipment(Net PPE) was $0.43 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.08 Mil.
Selling, General, & Admin. Expense(SGA) was $0.51 Mil.
Total Current Liabilities was $0.07 Mil.
Long-Term Debt & Capital Lease Obligation was $0.30 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.01 / 0.077) / (0.008 / 0.035)
=0.12987 / 0.228571
=0.5682

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-0.115 / 0.035) / (0.061 / 0.077)
=-3.285714 / 0.792208
=-4.1475

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.839 + 0.004) / 0.843) / (1 - (1.672 + 0.428) / 2.111)
=0 / 0.005211
=0

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.077 / 0.035
=2.2

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.084 / (0.084 + 0.428)) / (0.001 / (0.001 + 0.004))
=0.164063 / 0.2
=0.8203

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0.328 / 0.077) / (0.508 / 0.035)
=4.25974 / 14.514286
=0.2935

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 0.002) / 0.843) / ((0.297 + 0.069) / 2.111)
=0.002372 / 0.173378
=0.0137

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1.034 - -0.727 - -0.262) / 0.843
=-0.053381

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Doseology Sciences has a M-score of -4.76 suggests that the company is unlikely to be a manipulator.


Doseology Sciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Doseology Sciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Doseology Sciences (Doseology Sciences) Business Description

Traded in Other Exchanges
Address
116 - 5100 Anderson Way, Unit 197, Vernon, BC, CAN, V1T 0C4
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. Doseology offers cutting-edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

Doseology Sciences (Doseology Sciences) Headlines

From GuruFocus

Doseology Opens to American Investors

By PRNewswire PRNewswire 07-01-2022

Doseology Announces CEO Transition

By PRNewswire PRNewswire 03-31-2023

Doseology Opens to American Investors

By PRNewswire PRNewswire 06-21-2022

Doseology Welcomes New CFO

By PRNewswire PRNewswire 03-03-2023

Doseology Opens to American Investors

By PRNewswire PRNewswire 06-11-2022

Doseology Uplists to OTCQB Market in USA

By PRNewswire PRNewswire 07-06-2022

Doseology Announces New Director and Corporate Secretary

By PRNewswire PRNewswire 05-05-2023

Doseology Opens to American Investors

By PRNewswire PRNewswire 06-01-2022

Doseology Provides Corporate Update

By PRNewswire PRNewswire 01-23-2023